The FDA completed a draft guidance that would allow drugmakers to avoid paying rebates to pharmacy benefit managers and payers, according to BioCentury.
The creation of the legal loophole is included in the FDA's guidance on drug importation. The FDA said the guidance is intended to allow drugmakers to sell imported products at lower net prices that aren't inflated due to rebate payments.
If the guidance is approved, it could enabl
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,